Occurrence of Other Primary Malignancies in Patients with Endocrine Tumors of the Digestive Tract and Pancreas Abstract #186

Introduction: Endocrine tumors of the digestive tract and pancreas (GEP-NET) are often considered to be associated with other primary malignancies.
Aim(s): Further differentiation between previous, synchronous and metachronous lesions, studying 491 consecutive single center GEP-NET patients.
Materials and methods: Two-hundred and fifty-eight men and 233 women with GEP-NET (median age: 58 years) diagnosed between 2000-2009. The timeline, before-at-after diagnosis and type of other malignancies was studied using person-year methodology. Poisson distributions were used for testing of statistical significance. Data were linked to the National Cancer Registry.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kimberly Kamp

To read results and conclusion, please login ...

Further abstracts you may be interested in

#467 Thoracic and Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) and Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS)
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, mostly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence of EAS in the setting of patients diagnosed with thoracic or gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) is virtually absent.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Drs. Kimberly Kamp
Keywords: ACTH, GEP-NETS, Cushing
#544 Second Primary Tumor in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): Data From a Retrospective Observational Unicentric Study
Introduction: It is known that GEPNETs are associated with a high incidence of second primary tumors, especially in the context of inherited syndromes and synchronous injuries to the intestine.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#1112 Second Primary Malignancies in Patients with Neuroendocrine Tumors
Introduction: Numerous studies have demonstrated an elevated incidence of second primary malignancies (SPM) in patients with neuroendocrine tumours (NET).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Ashley Clift
#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression
Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Prof Rachel Riechelmann
#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study
Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Massironi